Azerbaijan Registration Refusals: The 4 Statutory Grounds and the 2-Day Notice

1. Key takeaways

Article 5.1 sets out four grounds for refusal of state registration (re-registration) and modification of registration:

5.1.1 the documents listed in Parts 3 and 4 have not been submitted in full, and the deficiency has not been remedied under Article 52 of the Administrative Procedure Code;

5.1.2 untrue information has been found in the submitted documents;

5.1.3 for medicinal products and drug substances, the conclusion of the expertise opinion issued by the institution is negative (not applicable to devices);

5.1.4 inconsistencies related to quality, effectiveness or safety have been found in the submitted device documents.

Article 5.2 provides that where a refusal decision is issued, the applicant must be informed by registered mail within 2 working days.

For foreign applicants the practical exposure concentrates in two places: internal consistency across the dossier (5.1.4) and document authenticity management (5.1.2), both of which can be engineered away before submission.

2. Legal basis

• Resolution No. 345 of the Cabinet of Ministers of the Republic of Azerbaijan dated 18 July 2024 on the Rules for State Registration of Medicines, Drug Substances and Medical Devices, Their Entry into the State Register and Maintenance of the State Register (effective 19 July 2024; Xalq qəzeti No. 151 of 20 July 2024; Legislative Bulletin 2024 No. 7, item 906; repealing Resolution No. 108 of 13 July 2007 as of 20 July 2024): Articles 5.1.1 to 5.1.4 (the four grounds for refusal), Article 5.2 (information by registered mail within 2 working days), Article 7.5 (refusal to consider on expiry of the remedy, notice within 2 working days), Article 7.6 (re-application possible).
• Administrative Procedure Code of the Republic of Azerbaijan, Article 31 (acceptance and registration of applications) and Article 52 (remedy of deficiencies) — specifically Article 52 (remedy of deficiencies).
• Law of the Republic of Azerbaijan on Medicines (Law No. 208-IIIQ, adopted 22 December 2006, effective 28 February 2007, Legislative Bulletin 2007 No. 2, item 70), as amended by Law No. 979-VIQD of 14 July 2023 (adding Articles 1-1 and 9-1, Legislative Bulletin 2023 No. 8, item 1127): Article 1.0.14 (definition of device quality: conformity with the requirements of relevant technical regulatory legal acts and the documents issued by the manufacturer on that basis).

3. Expert insights

Insight one: two of the four grounds form a medicines-only / devices-only mirror pair. Article 5.1.3 governs only medicinal products and drug substances (a negative expertise opinion), while Article 5.1.4 governs only devices (inconsistencies related to quality, effectiveness or safety found in the documents). The legislator deliberately separated the veto logic: devices do not fail through a negative expertise opinion; the device veto is documentary self-contradiction.

Insight two: the benchmark for Article 5.1.4 is Article 1.0.14. Article 1.0.14 of the Law on Medicines defines device quality as the state in which the device conforms to relevant technical regulatory legal acts and to the documents the manufacturer issues on that basis. The typical shape of an inconsistency is therefore: the risk degree written in the 4.2.8 conformity declaration, the scope in the 4.2.3 brief description, the coverage of the 4.2.9 QMS certificate and the product names on the 4.2.2 foreign registration certificate failing to match one another.

Insight three: Article 5.1.2 (untrue information) and Article 5.1.4 (inconsistency) are two different kinds of risk. The former concerns authenticity (forged, expired or mismatched documents); the latter concerns logical consistency (genuine documents that contradict each other). The statement in the Annex 1 application form acknowledging criminal liability for the use of forged documents exists precisely for Article 5.1.2.

Insight four: the remedies for refusal and for refusal-to-consider differ. Article 5.2 only requires the applicant to be informed; it prescribes no remedy, while Article 7.6 expressly allows re-application after a refusal to consider. The practical estimate is: after receiving a refusal, first locate the ground under Article 5.1 — a 5.1.1 case can be remedied and resubmitted, while 5.1.2 or 5.1.4 cases require a new approach (new documents, new models, new classification). Specific remedies follow the Administrative Procedure Code and the Law on Licenses and Permits (pending verification, case-by-case local counsel advice recommended).

Insight five: the 2-working-day registered-mail delivery is a substantive risk for foreign applicants. Article 5.2 requires information by registered mail. Where the certificate holder or applicant is a local entity without Azerbaijani language capacity, or where an address change was never notified to the Ministry, the refusal decision can take effect without the applicant knowing. The power of attorney must state the forwarding obligation and its deadline.

4. Practical recommendations

1. Before submission, run a four-document cross-check: the risk degree in the conformity declaration, the scope in the brief description, the QMS certificate coverage and the product names on the foreign registration certificate must match verbatim.
2. Have the authenticity statement of the Annex 1 application form signed by an authorised signatory and verify the signatory’s identity against the authorisation documents.
3. On receiving a refusal, locate the ground under 5.1.1 to 5.1.4 first: remedy and resubmit for 5.1.1; change the approach for 5.1.2 and 5.1.4.
4. State in the power of attorney and internal procedures that the local entity forwards official mail to the foreign manufacturer within 1 working day of receipt.
5. Notify the Ministry of Health and AEC in parallel whenever addresses or contacts change, so the 2-working-day delivery never falls into a void.
6. For technical inconsistencies likely to trigger Article 5.1.4 (such as model naming rules), unify the full terminology table before submission.

5. Verification checklist

• □ The four-document cross-check is complete (conformity declaration / brief description / QMS certificate / foreign registration certificate).
• □ The Annex 1 application form is signed by an authorised signatory whose identity has been verified.
• □ Refusal contingency plans classified under 5.1.1 to 5.1.4 are in place.
• □ The power of attorney states the 1-working-day forwarding duty of the local entity.
• □ Address and contact changes feed a parallel notification mechanism to the Ministry of Health and AEC.
• □ Model naming and technical terminology have been unified across the full table.

• Article 19 — The 5-day notice and 10-day remedy: deficiency handling and suspension of deadlines: https://www.grzanglobal.com/azerbaijan-medical-device-registration/deficiency-notice-5-days-remedy-10-days/
• Article 18 — Certificate issued in 7 working days: there are actually two start points: https://www.grzanglobal.com/azerbaijan-medical-device-registration/certificate-issued-in-7-working-days/
• Article 13 — The 11 dossier items one by one: 4.2.1 to 4.2.11: https://www.grzanglobal.com/azerbaijan-medical-device-registration/dossier-11-items-breakdown/

Regulatory information verified as of October 30, 2026.

GRZAN supports manufacturers and authorised representatives in pre-empting refusals for medical device registration in Azerbaijan, from four-document consistency cross-checks and Annex 1 signatory management to ground-by-ground refusal response planning. For tailored assistance with your Azerbaijan registration strategy, contact us at info@grzanglobal.com.